| Symbol | EFTR |
|---|---|
| Name | EFFECTOR THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 92075 United States MA 124 Washington Street, Suite 101 |
| Telephone | +1 (508) 543-1720 |
| Fax | — |
| — | |
| Website | https://effector.com/ |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Ernst & Young LLP; |
| Audit Status | AUDITED |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001828522 |
| Description | eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. Additional info from OTC: |
Pink Limited symbol attribute type Security_Name was changed. Previous value: -. New value: EFFECTOR THERAPUTCS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: EFFECTOR THERAPUTCS INC.
Read moreNew Form EFFECT - eFFECTOR Therapeutics, Inc. Filed: 2024-08-01 AccNo: 9999999995-24-002348 Size: 1 KB
Read moreNew Form S-8 POS - eFFECTOR Therapeutics, Inc. Filed: 2024-07-30 AccNo: 0001193125-24-188897 Size: 19 KB
Read moreNew Form POS AM - eFFECTOR Therapeutics, Inc. Filed: 2024-07-30 AccNo: 0001193125-24-188868 Size: 20 KB
Read moreNew Form POS AM - eFFECTOR Therapeutics, Inc. Filed: 2024-07-30 AccNo: 0001193125-24-188859 Size: 20 KB
Read moreNew Form POS AM - eFFECTOR Therapeutics, Inc. Filed: 2024-07-30 AccNo: 0001193125-24-188848 Size: 20 KB
Read moreNew Form 25-NSE - eFFECTOR Therapeutics, Inc. Filed: 2024-07-19 AccNo: 0001354457-24-000516 Size: 3 KB
Read moreeFFECTOR Therapeutics, Inc. (EFTR) was added to the list of traded instruments on Pink Current exchange
Read moreeFFECTOR Therapeutics Inc. (EFTR) was removed from the list of traded instruments on NASDAQ exchange
Read more